Clinical trial · no report yet · Phase 2
NCT05501704
ETHAN - ET for Male BC
- NCT05501704 ↗
- Recruiting
- Jose Pablo Leone
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 3 |
The trial
ClinicalTrials.gov- Official title
- ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast caNcer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma
- Interventions
- Tamoxifen; Anastrozole; Degarelix; Abemaciclib
- Arms
- Window Phase Arm A: Tamoxifen · Experimental
- Window Phase Arm B: Anastrozole · Experimental
- Window Phase Arm C: Anastrozole + Degarelix · Experimental
- Neoadjuvant Phase Arm D: Tamoxifen · Experimental
- Neoadjuvant Phase Arm E: Tamoxifen + Abemaciclib · Experimental
- Neoadjuvant Phase Arm F: Anastrozole and Degarelix · Experimental
- Neoadjuvant Phase Arm G: Anastrozole + Degarelix + Abemaciclib · Experimental
- Enrollment
- 60 (estimated)
- Primary outcomes
- Change in Ki-67
- RCB index
- Sponsor
- Jose Pablo Leone with Eli Lilly and Company, Translational Breast Cancer Research Consortium
- Start
- Oct 11, 2023
- Primary completion
- Apr 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05501704 · updated Aug 24, 2026